Nature Communications (Nov 2019)
A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension
- Nadine D. Arnold,
- Josephine A. Pickworth,
- Laura E. West,
- Sarah Dawson,
- Joana A. Carvalho,
- Helen Casbolt,
- Adam T. Braithwaite,
- James Iremonger,
- Lewis Renshall,
- Volker Germaschewski,
- Matthew McCourt,
- Philip Bland-Ward,
- Hager Kowash,
- Abdul G. Hameed,
- Alexander M. K. Rothman,
- Maria G. Frid,
- A. A. Roger Thompson,
- Holly R. Evans,
- Mark Southwood,
- Nicholas W. Morrell,
- David C. Crossman,
- Moira K. B. Whyte,
- Kurt R. Stenmark,
- Christopher M. Newman,
- David G. Kiely,
- Sheila E. Francis,
- Allan Lawrie
Affiliations
- Nadine D. Arnold
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- Josephine A. Pickworth
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- Laura E. West
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- Sarah Dawson
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- Joana A. Carvalho
- Kymab Ltd, Babraham Research Campus
- Helen Casbolt
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- Adam T. Braithwaite
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- James Iremonger
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- Lewis Renshall
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- Volker Germaschewski
- Kymab Ltd, Babraham Research Campus
- Matthew McCourt
- Kymab Ltd, Babraham Research Campus
- Philip Bland-Ward
- Kymab Ltd, Babraham Research Campus
- Hager Kowash
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- Abdul G. Hameed
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- Alexander M. K. Rothman
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- Maria G. Frid
- Cardiovascular Pulmonary Research Laboratories, Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus
- A. A. Roger Thompson
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- Holly R. Evans
- Department of Chemistry, University of Sheffield
- Mark Southwood
- Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke’s and Papworth Hospital
- Nicholas W. Morrell
- Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke’s and Papworth Hospital
- David C. Crossman
- School of Medicine, University of St. Andrews, St
- Moira K. B. Whyte
- MRC/University of Edinburgh Centre for Inflammation Research, University of Edinburgh, The Queens Medical Research Institute
- Kurt R. Stenmark
- Cardiovascular Pulmonary Research Laboratories, Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus
- Christopher M. Newman
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- David G. Kiely
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- Sheila E. Francis
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- Allan Lawrie
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield
- DOI
- https://doi.org/10.1038/s41467-019-13139-9
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 18
Abstract
Pulmonary arterial hypertension (PAH) is characterised by progressive pulmonary vascular remodelling. Here, Arnold et al. develop a therapeutic antibody targeting osteoprotegerin and find it attenuates pulmonary vascular remodelling in multiple rodent models of PAH, alone or in combination with standard of care vasodilator therapy.
